High-level advocacy for diabetes research in Horizon 2020
Advocacy with the European institutions was the original motivation to create EURADIA, which emerged from a collaboration of leadership of European diabetes NGOs (academic science, people with diabetes and health professionals) and a number of pharmaceutical companies that approached the Commission in unison to voice their concern that diabetes had not been included in the Sixth Framework Research Programme (FP6). EURADIA has now developed a proactive stance especially within the current discussions over Horizon 2020.
EURADIA is following Horizon 2020 legislation (and other relevant programmes) with individual MEPs and committees in Parliament to promote diabetes research. When the programmes are running EURADIA aims to advocate to ensure contact with European Commission staff and committees to ensure that diabetes research retains a high profile. EURADIA provides Parliament and Commission with information about diabetes research.
EURADIA works independently and together with other organisations including the European Coalition for Diabetes (ECD), which have a wider scope beyond diabetes research. Diabetes research can be highlighted at specific events in the European Parliament and Commission calendars. In discussions on diabetes research it is important to highlight the European Parliament Resolution for the EU Diabetes Epidemic.
Information on Horizon 2020 can be found here
Background to health research in Horizon 2020
- On 30 November 2011 the Commission published a package of proposals for Horizon 2020, a new €80 billion EU Framework Programme for Research and Innovation for 2014-2020
- Horizon 2020 is structured around three pillars:
- Excellent Science
- Industrial Leadership
- Societal Challenges
- Health is addressed under Horizon 2020’s third pillar on Societal Challenges which allocates €9,077 billion to tackle “Health, demographic change and wellbeing”
- Diabetes is mentioned as one of the chronic conditions, which are major causes of disability, ill health and premature death, and present considerable social and economic costs. In the current economic context and given the rising cost of health and social care, the Commission highlights the need for an appropriate European level response to research and innovation in the area of chronic diseases.